Medpace (NASDAQ:MEDP) CEO Sells 21,883 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 21,883 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $623.29, for a total transaction of $13,639,455.07. Following the sale, the chief executive officer owned 482,390 shares in the company, valued at $300,668,863.10. This trade represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Medpace Stock Down 2.1%

Shares of NASDAQ:MEDP traded down $13.04 during midday trading on Wednesday, reaching $617.15. 272,881 shares of the company were exchanged, compared to its average volume of 333,111. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a fifty day simple moving average of $589.62 and a two-hundred day simple moving average of $513.16. The firm has a market cap of $17.22 billion, a PE ratio of 36.18, a P/E/G ratio of 2.78 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Hedge Funds Weigh In On Medpace

Several hedge funds have recently modified their holdings of MEDP. BlackRock Inc. bought a new stake in Medpace during the second quarter worth about $1,323,047,000. State Street Corp raised its stake in shares of Medpace by 4.2% during the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock worth $376,483,000 after purchasing an additional 28,666 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Wasatch Advisors LP boosted its holdings in shares of Medpace by 19.4% in the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after buying an additional 125,625 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Medpace by 8.3% in the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after buying an additional 38,760 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of a number of research reports. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Truist Financial boosted their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average target price of $595.20.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.